Clinigen Group PLC Rating Reiterated by Oriel Securities Ltd (CLIN)
Clinigen Group PLC (LON:CLIN)‘s stock had its “buy” rating reiterated by investment analysts at Oriel Securities Ltd in a note issued to investors on Thursday. They currently have a GBX 650 ($11.11) target price on the stock. Oriel Securities Ltd’s price objective suggests a potential upside of 62.50% from the company’s current price.
Clinigen Group PLC (LON:CLIN) traded up 0.70% on Thursday, hitting GBX 397.50. The stock had a trading volume of 1,021,891 shares. Clinigen Group PLC has a one year low of GBX 339.00 and a one year high of GBX 690.00. The stock has a 50-day moving average of GBX 399.2 and a 200-day moving average of GBX 500.4.
CLIN has been the subject of a number of other recent research reports. Analysts at Numis Securities Ltd reiterated a “buy” rating on shares of Clinigen Group PLC in a research note on Friday, July 11th. They now have a GBX 650 ($11.11) price target on the stock. Analysts at Investec upgraded shares of Clinigen Group PLC to a “buy” rating in a research note on Monday, July 7th. They now have a GBX 497 ($8.49) price target on the stock, down previously from GBX 560 ($9.57).
Clinigen Group plc (LON:CLIN) is a specialty pharmaceuticals and services business company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.